Intestinal Biotech Development
Intestinal Biotech Development specializes in research services related to digestive diseases, including all aspects of intestinal and hepatic inflammation, visceral pain, and metabolic issues. They collaborate with clinicians and academic research centers dedicated to IBD, partnering with researchers, pharmaceutical, and food ingredient companies to develop marketed medicines and food ingredients. Their focus is solely on IBD research, aiming to address unmet medical needs and improve gut health through innovative therapies and food ingredients.
Industries
Nr. of Employees
small (1-50)
Intestinal Biotech Development
Faculté de Médecine, Pole Recherche, Amphi JK, Bd. du Pr. Jules Leclercq, 59045 Lille Cedex, France
Services
Preclinical evaluation of anti-inflammatory properties of compounds, probiotics or food ingredients using in vitro cell systems and multiple in vivo animal models of colitis, IBS and related assays.
Animal models and assays for hepatic inflammation, fibrosis and liver regeneration, and metabolic disorder models including obesity and diabetes with metabolic and adipogenesis assessments.
Execution of Phase I clinical trials in collaboration with a clinical investigation center and recruitment via a regional network of gastroenterologists to evaluate safety and early signals for intestinal indications.
Proof-of-concept preclinical tests and clinical studies for food ingredient companies to evaluate effects on intestinal comfort, visceral pain and other functional gut outcomes required for claim substantiation.
Screening of promising molecules at early development stages using in vitro assays and animal models focused on digestive tract pathologies.
Preclinical evaluation of anti-inflammatory properties of compounds, probiotics or food ingredients using in vitro cell systems and multiple in vivo animal models of colitis, IBS and related assays.
Animal models and assays for hepatic inflammation, fibrosis and liver regeneration, and metabolic disorder models including obesity and diabetes with metabolic and adipogenesis assessments.
Execution of Phase I clinical trials in collaboration with a clinical investigation center and recruitment via a regional network of gastroenterologists to evaluate safety and early signals for intestinal indications.
Proof-of-concept preclinical tests and clinical studies for food ingredient companies to evaluate effects on intestinal comfort, visceral pain and other functional gut outcomes required for claim substantiation.
Screening of promising molecules at early development stages using in vitro assays and animal models focused on digestive tract pathologies.
Expertise Areas
- Inflammatory bowel disease (IBD) research
- Preclinical animal modeling (IBD, IBS, hepatic inflammation, metabolic disorders)
- Clinical trial management (Phase I)
- Microbiome and gut flora analysis
Key Technologies
- Real-time PCR
- ELISA
- Western Blot
- Immunohistochemistry
News & Updates
Bringing Novel Ideas into Innovative Medicine
Overview of progress in digestive disease treatments, emphasizing unmet needs and research goals.
Clinical Trial Services Collaboration
Partnership with Lille University Hospital for Phase I clinical trials, including for ulcerative colitis.
Research on Gut Microbiota and IBD
Exploration of the role of intestinal microbes in IBD pathogenesis and potential therapeutic targets.
In Vivo Models for IBS and IBD
Use of validated animal models to evaluate effects of compounds on intestinal well-being and inflammation.
Animal Models for IBD and Liver Diseases
Various models including chemically induced colitis, genetically modified mice, and liver inflammation models.
Metabolic Disorder Animal Models
Models for diabetes, obesity, NASH, and related metabolic issues, including probiotic effects.
Bringing Novel Ideas into Innovative Medicine
Overview of progress in digestive disease treatments, emphasizing unmet needs and research goals.
Clinical Trial Services Collaboration
Partnership with Lille University Hospital for Phase I clinical trials, including for ulcerative colitis.
Research on Gut Microbiota and IBD
Exploration of the role of intestinal microbes in IBD pathogenesis and potential therapeutic targets.
In Vivo Models for IBS and IBD
Use of validated animal models to evaluate effects of compounds on intestinal well-being and inflammation.
Animal Models for IBD and Liver Diseases
Various models including chemically induced colitis, genetically modified mice, and liver inflammation models.
Metabolic Disorder Animal Models
Models for diabetes, obesity, NASH, and related metabolic issues, including probiotic effects.